Clinical Read2026-06-02

FID-007 with cetuximab

Name: FID-007 with cetuximab
Start: 2026-06-02

Fulgent Genetics Inc.FLGT

Indication: Recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)
Stage: phase2
Event: Phase 2